Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer
de Bono J, Scranton J, Wang T, Hudes G, Gillessen Sommer S, Fong P, Sandhu S, Aparicio L, Saad F, Petrylak D, Pandha H, Piulats J, Pollak M. Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer. Clin Cancer Res 2014; 20:1925-34.
17.02.2014
Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer
17.02.2014
Clin Cancer Res 2014; 20:1925-34
de Bono Johann S, Scranton Judith, Wang Tao, Hudes Gary R, Gillessen Sommer Silke, Fong Peter, Sandhu Shahneen K, Aparicio Luis Miguel A, Saad Fred, Petrylak Daniel P, Pandha Hardev S, Piulats Josep M, Pollak Michael N
Weiter
